Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Umbilical cord stem cells tested for liver cirrhosis – early results promising?

NCT ID NCT05331872

Disease control Sponsor: Vinmec Research Institute of Stem Cell and Gene Technology Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested whether stem cells from donated umbilical cords are safe for people with liver cirrhosis. Twenty adults received an infusion of these cells and were monitored for a year. The main goal was to check for side effects, but researchers also looked for signs of improved liver function.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
human umbilical cord-derived mesenchymal stem cells
What this could lead to
If it works, this could point toward a new cell-based treatment to improve liver function in cirrhosis patients.
What could go wrong
This is a very early Phase 1 trial with only 20 people, so it mainly checks safety, not effectiveness. The stem cells may not improve liver function, and there are risks like infection or allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

20 people

The number who actually took part.

Started

Jan 2021

Finished

Sep 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18 to 70 years old. * Patients diagnosed of liver cirrhosis: splenomegaly, elevated hepatic enzymes and/or esophageal varices detected by endoscopy, or liver biopsy demonstrated liver cirrhosis * Be willing to complete the study and sign the consent form. Exclusion Criteria: * Younger than 18 or older than 70 years old * Recent infection * Patients with history of chronic diseases such as cancer, chronic hepatitis, chronic kidney disease. * Any clinically significant blood coagulation disorder(s)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Liver cirrhosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cirrhosis of liver

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Liver cirrhosis

Contacts and locations

Locations

  • Vinmec Research Institute of Stem Cell and Gene Technology

    Hanoi, Hanoi, 100000, Vietnam

More trials for these conditions

Other studies related to the condition(s) this trial covers.